These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 17904830

  • 1. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
    Girona J, Manzanares JM, Marimón F, Cabré A, Heras M, Guardiola M, Ribalta J, Masana L.
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
    [Abstract] [Full Text] [Related]

  • 2. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus.
    Leinonen JS, Rantalaiho V, Laippala P, Wirta O, Pasternack A, Alho H, Jaakkola O, Ylä-Herttuala S, Koivula T, Lehtimäki T.
    Free Radic Res; 1998 Aug; 29(2):137-41. PubMed ID: 9790515
    [Abstract] [Full Text] [Related]

  • 3. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome.
    Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P.
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1545-50. PubMed ID: 16627808
    [Abstract] [Full Text] [Related]

  • 4. Paraoxonase-1 (PON-1) genotype and activity and in vivo oxidized plasma low-density lipoprotein in Type II diabetes.
    Sampson MJ, Braschi S, Willis G, Astley SB.
    Clin Sci (Lond); 2005 Aug; 109(2):189-97. PubMed ID: 15853770
    [Abstract] [Full Text] [Related]

  • 5. Oxidized LDL and anti-oxLDL antibody levels in peripheral atherosclerotic disease.
    Andican G, Seven A, Uncu M, Cantaşdemir M, Numan F, Burçak G.
    Scand J Clin Lab Invest; 2008 Aug; 68(6):473-8. PubMed ID: 18609113
    [Abstract] [Full Text] [Related]

  • 6. [Antibodies against low density oxidized lipoproteins in type 2 diabetics].
    Malícková K, Skrha J, Janatková I, Vanková Z, Fucíková T.
    Epidemiol Mikrobiol Imunol; 2004 Aug; 53(3):131-5. PubMed ID: 15524272
    [Abstract] [Full Text] [Related]

  • 7. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
    Quéméneur T, Martin-Nizard F, Kandoussi A, Kyndt X, Vanhille P, Hachulla E, Hatron PY, Fruchart JC, Duriez P, Lambert M.
    Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573
    [Abstract] [Full Text] [Related]

  • 8. Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.
    Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z.
    Acta Biochim Pol; 2006 Dec; 53(4):783-7. PubMed ID: 17106515
    [Abstract] [Full Text] [Related]

  • 9. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis.
    Peters MJ, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, Dijkmans BA, Voskuyl AE.
    J Rheumatol; 2008 Aug; 35(8):1495-9. PubMed ID: 18597411
    [Abstract] [Full Text] [Related]

  • 10. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
    Lopes-Virella MF, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, Forrest KY.
    Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
    [Abstract] [Full Text] [Related]

  • 11. The effects of metabolic control on oxidized low-density lipoprotein antibodies in children and adolescents with type 1 diabetes mellitus.
    Kara C, Cetinkaya S, Sezgin N, Kinik ST.
    Pediatr Diabetes; 2008 Feb; 9(1):17-22. PubMed ID: 18211632
    [Abstract] [Full Text] [Related]

  • 12. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
    Griffin ME, McInerney D, Fraser A, Johnson AH, Collins PB, Owens D, Tomkin GH.
    Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
    [Abstract] [Full Text] [Related]

  • 13. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus.
    Lopez LR, Hurley BL, Simpson DF, Matsuura E.
    Ann N Y Acad Sci; 2005 Jun; 1051():97-103. PubMed ID: 16126948
    [Abstract] [Full Text] [Related]

  • 14. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
    Turk Z, Sesto M, Skodlar J, Ferencak G, Turk N, Stavljenić-Rukavina A.
    Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
    [Abstract] [Full Text] [Related]

  • 15. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F, Cofan M, Campos B, Guerra R, Campistol JM, Oppenheimer F.
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [Abstract] [Full Text] [Related]

  • 16. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M, Kiechl S, Tsimikas S, Miller E, Sheldon J, Willeit J, Witztum JL, Xu Q.
    J Am Coll Cardiol; 2006 Jun 20; 47(12):2436-43. PubMed ID: 16781371
    [Abstract] [Full Text] [Related]

  • 17. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO, Fonseca FA, Fischer SM, Monteiro CM, Brandão SA, Póvoa RM, Bombig MT, Carvalho AC, Monteiro AM, Ramos E, Gidlund M, Figueiredo Neto AM, Izar MC.
    Clin Chim Acta; 2009 Aug 20; 406(1-2):113-8. PubMed ID: 19523463
    [Abstract] [Full Text] [Related]

  • 18. Oxidized low-density lipoproteins, autoantibodies against oxidized low-density lipoproteins and carotid intima media thickness in a clinically healthy population.
    Chen HW, Kuo CL, Huang CS, Kuo SJ, Liu CS.
    Cardiology; 2008 Aug 20; 110(4):252-9. PubMed ID: 18073481
    [Abstract] [Full Text] [Related]

  • 19. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome.
    Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, Burkhard PR, Mensi N, Righini M, Reber G, James R, Mach F, Chevrolet JC, Dayer JM, Frostegard J, Roux-Lombard P.
    Clin Sci (Lond); 2008 Jul 20; 115(1):25-33. PubMed ID: 18088236
    [Abstract] [Full Text] [Related]

  • 20. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.
    Mastorikou M, Mackness M, Mackness B.
    Diabetes; 2006 Nov 20; 55(11):3099-103. PubMed ID: 17065348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.